Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: Results from a multiple-attack study

Cephalalgia

Volumn 25, Issue 9, 2005, Pages 726-734

  Martin, Vincent T ^a   Loder, E ^b   Taylor, K ^c   Almas, M ^c   Hilliard, B ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^c PFIZER INC   (United States)

Author keywords

Butalbital; Eletriptan; Headache; Migraine; Triptan

Indexed keywords

ACETYLSALICYLIC ACID PLUS BUTALBITAL PLUS CAFFEINE; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; ELETRIPTAN;

ADULT; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FATIGUE; FEMALE; FUNCTIONAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; MIGRAINE; MUSCLE HYPERTONIA; NAUSEA; OPEN STUDY; OTALGIA; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENCE RISK; SOMNOLENCE; THORAX PAIN;

ACETAMINOPHEN; ADOLESCENT; ADULT; ANALGESICS; ASPIRIN; BARBITURATES; CAFFEINE; DRUG COMBINATIONS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; PYRROLIDINES; QUALITY OF LIFE; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 23944485645     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00963.x     Document Type: Article

References (36)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl 7:1-96.
2. Tfelt-Hansen P, Block G, Dahlöf C, Diener H-C, Ferrari MD, Goadsby PJ et al. International Headache Society Clinical Trials Subcommittee. Guidelines for Controlled Trials of Drugs in Migraine, 2nd edn. Cephalalgia 2000; 20:765-86.
3. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754-62.
4. Aukerman G, Knutson D, Miser WF. Management of the acute migraine headache. Am Fam Physician 2002; 66:2123-30.
5. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. MIPCA Migraine Guidelines Development Group. Migraine in Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002; 18:414-39.
6. Rollins G. Migraine sufferers are not seeking nor receiving guideline-based care. Rep Med Guidel Outcomes Res 2002; 13:7-9.
7. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58:885-94.
8. Silberstein SD, McCory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 2001; 41:953-67.
9. Sellers EM, Hoornweg K, Busto UE, Romach MK. Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999; 6:18-25.
10. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995; 36 Suppl 2:S46-S65.
11. Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy 2002; 22:1029-35.
12. Carlsten A, Allebeck P, Brant L. Are suicide rates in Sweden associated with changes in the prescribing of medicines? Acta Psychiatr Scand 1996; 94:94-100.
13. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992; 327:1109-14.
14. van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. BMJ 1990; 300:1558-9.
15. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999; 39:190-6.
16. Scher A, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998; 38:497-506.
17. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache 2003; 43:179-90.
18. Scher AI, Lipton RB, Stewart W. Risk factors for chronic daily headache. Curr Pain Headache Rep 2002; 6:486-91.
19. Johnson DE, Rollema H, Schmidt AW, McHarg AD. Serotonergic effects and extracellular brain levels of eletriptan, naratriptan and sumatriptan in rat brain. Eur J Pharmacol 2001; 425:203-10.
20. Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044), a potent and novel 5-HT (1B/1D) receptor agonist. Eur J Pharmacol 2000; 398:73-81.
21. Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R. Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999; 368:259-68.
22. Chia Y-C, Lim S-H, Wang S-J, Cheong YM, Denaro J, Hettiarachchi J. Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatories. Headache 2003; 43:984-90.
23. Färkkilä M, Olesen J, Dahlöf C, Stovner L, ter Bruggen JP, Rasmussen S, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23:198-203.
24. Davies GM, Santanello N, Gerth W, Lerner D, Block GA. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999; 19:497-502.
25. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998; 38:295-302.
26. Gallagher RM, Dennish G, Spierings EL, Chitra R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000; 40:119-28.
27. Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Rosjo O, Millson DS. Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur J Neurol 2001; 8:237-45.
28. Pascual J, Falk R, Docekal R, Prusinski A, Jelencsik J, Cabarrocas X, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001; 45:206-13.
29. Bussone G, Manzoni GC, Cortelli P, Roncolato M, Fabbri L, Benassuti C. Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. Neurol Sci 2000; 21:272-8.
30. Bomhof MA, Heywood J, Pradalier A, Enahoro H, Winter P, Hassani H. Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Cephalalgia 1998; 18:33-7.
31. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT (1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
32. Maizels M. Health resource utilization of the emergency department headache 'repeater'. Headache 2002; 42:747-53.
33. Diamond ML, Hettiarachchi JS, Hilliard B, Sands G, Nett R. Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004; 44:209-16.
34. Schoenen J, Pascual J, Rasmussen S, Sun W, Sikes C, Hettiarachchi J. Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol 2005; 12:108-17.
35. Linde K, Scholz M, Melchart D, Willich SN. Should systematic reviews include non-randomized and uncontrolled studies? The case of acupuncture for chronic headache. J Clin Epidemiol 2002; 55:77-85.
36. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. J Am Med Assoc 2001; 286:821-230.